Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis.
about
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsSimultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.Design of (Gd-DO3A)n-polydiamidopropanoyl-peptide nucleic acid-D(Cys-Ser-Lys-Cys) magnetic resonance contrast agents.Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization.Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy.GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration.Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic applicationRegulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy.The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cellsExtracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification.Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7)A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells.Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation.Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention.Allosteric IGF-1R Inhibitors.Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2.PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation.Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.Involvement of two distinct signalling pathways in IGF-1-mediated central control of hypotensive effects in normotensive and hypertensive rats.Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
P2860
Q24810622-A71580C0-3FBD-4726-A4E3-4504335C4599Q31016741-860E4BF9-ACA1-4A68-8402-ACD2462CB272Q31168690-43907762-E764-4D33-AD71-81CE9E5C9F21Q33232494-F6ACAF04-86C1-4463-8503-9A4CD2B7E5AEQ33391425-15E855B1-585F-4E34-B088-77FE359351DBQ33436873-34920C32-3E75-4B7E-A915-39CEDDBB5259Q33959016-C4C13D33-B638-4B0F-92B6-CFEE979C089DQ34612359-798A81B2-F609-4013-9319-3A3E37A13E23Q35094666-1013DFF7-71E3-4035-A80A-8CF76A63F337Q35919819-9F630AED-593F-4403-8127-1BA4CDD1B44EQ36062128-B0FFA86F-B3E5-4B1D-89C9-4A89DD6E4FA4Q36287335-0A675F37-F9BC-4A01-952F-59D30BA4E058Q36562098-D44DDC5C-3014-4D8F-BE05-1045DBB06718Q36903909-44702451-3593-41F2-B423-6F717E986902Q36955067-87F11243-20A0-4C26-8820-CE4F5D76628EQ36996036-90E99DDC-A440-44BD-9497-BBA6C75C9DB0Q37395986-2A09CD67-2A01-4E45-A7FB-DB978DFED598Q37505197-B1932723-52E7-4EA4-BFFC-8E46E9423093Q37515263-C1DE3D9D-79DE-4BCF-B561-042386B53428Q37588787-8116E5C3-66D8-4A7B-B37D-C9CDFF725266Q38404608-1FEEC1E4-6D6C-4F5F-B9BA-A6D556A29B63Q38569799-0138A54E-44B2-4557-B26C-30108929A4B8Q38798785-A5BC5EC2-0C7F-4673-A8B9-68B9D5C5EB5FQ38914626-50C85FEF-835D-4A06-87E4-345FEB2E6F24Q38962349-DF88AF74-50EA-430B-B731-035DDBADDC54Q39156086-B15A2C47-DF25-4D2B-8791-BE2E6052FBC2Q39456277-D945D3EB-1DA1-4A23-BC78-A4C5D6030634Q39717036-D204D58D-0AA8-462C-B2E4-5992AABE7AADQ39769976-0DEAD838-2F63-4E6C-AA89-4C2EFDB4E364Q40390038-4C894488-7953-468D-AA9B-9B762B7D370EQ40448458-25CAB1FA-7C5F-426F-B456-2132B68B193EQ42635172-DBA5783A-9590-4C0D-AA8F-5E3359B54BBAQ43067025-6F109950-E444-4EBF-A38B-8BE51ED0914EQ43097453-693C3203-4EA9-452E-96FA-B3196CC9934AQ43141124-8A281C05-F6B1-40D4-9FAE-92A286F73CF7Q48260427-BEC3064F-440E-4C40-8857-73478F46937CQ49820985-4B4301D7-8AE8-46EE-AF1D-FE0C03BE894FQ53586091-CB32AA92-666F-4C4F-AB7B-6122E2FBF84B
P2860
Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@ast
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@en
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@nl
type
label
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@ast
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@en
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@nl
prefLabel
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@ast
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@en
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@nl
P356
P1476
Insulin-like growth factor rec ...... mation and inducing apoptosis.
@en
P2093
P304
P356
10.2174/1568009023333863
P577
2002-09-01T00:00:00Z